PracticeUpdate Dermatology Best of 2018

Indication: ILUMYA (tildrakizumab) is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. 1 Recommended dose: 100mg at weeks 0, 4 and every 12 weeks thereafter. 1

6 injections in rst 52 weeks

0 Week

4

8 12

16

20 24

28

32 36

40

44 48

52

Storage: Store at 2°C to 8°C. ILUMYA is stable for up to 30 days at 25°C. 1

PBS Information: Not PBS Listed

Please review Product Information before prescribing available from www.ebs.tga.gov.au or Sun Pharma by calling 1800 726 229 ILUMYA tildrakizumab (rch) 100 mg/1 mL solution for injection in pre-lled syringe. Indications: treatment of adults with moderate- to-severe plaque psoriasis who are candidates for systemic therapy. Contraindications: Hypersensitivity to the active substance or excipients. Clinically important active infections (e.g. active tuberculosis). Precautions: Infections: Chronic or a history of recurrent infections; monitor patients if a serious infection develops Active tuberculosis (TB); evaluate for TB prior to treatment. Consider anti-TB therapy in patients with history of latent or active TB in whom an adequate course of treatment cannot be conrmed. Monitor for TB during and after treatment. Hypersensitivity: Discontinue immediately if a serious reaction occurs and initiate appropriate therapy. Immunisations: Patients should not receive live vaccines during and for at least 17 weeks after treatment. Consider completion of immunisations prior to treatment initiation but if a live vaccine is received, wait at least 4 weeks prior to treatment initiation. Malignancy: Caution should be observed in patients with a history of malignancy or if this develops during therapy. Paediatric Use: not evaluated in under 18yr population. Interactions: Live vaccines. (See full PI). Pregnancy: (Category B1) Adverse effects: Common: diarrhoea, nausea, fatigue, injection site pain nasopharyngitis, sinusitis, arthralgia, back pain and pain in extremity. Dosage and administration: subcutaneous injection (100mg) at weeks 0, 4 and every 12 weeks thereafter. See Consumer Medicines Information for instructions. Storage: store in refrigerator (2ºC-8ºC). Do not freeze. ILUMYA is stable for up to 30 days at 25ºC. Protect from light. Do not shake. Store in original container until ready for use. Date of preparation: August 2018 ▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identication of new safety information. Healthcare professionals are asked to report any suspected adverse events at https://www.tga.gov.au/reporting-problems References: 1. Approved Product Information Sun Pharma ANZ Pty Ltd ABN 17 110 871 826, Macquarie Park NSW 2113. Ph: 1800 726 229. Fax: +61 2 8008 1639. Med Info and to report Adverse Events: adverse.events.aus@sunpharma.com or 1800 726 229. ILUMYA™ is a trade mark of Sun Pharma ANZ Pty Ltd. IL2018/12PUD1. Date of preparation: November 2018.